Biofrontera AG
B8FK
Company Profile
Business description
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
Contact
Hemmelrather Weg 201
LeverkusenNW51377
DEUT: +49 214876320
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
69
Stocks News & Analysis
stocks
ASX tech share upgraded following AI contract wins
Strong demand for AI infrastructure drives fair value lift.
stocks
5 star fully franked ASX dividend payer
Investors in cheap ASX share with a narrow moat enjoys a high yield, but there are risks investors should be aware of.
stocks
An undervalued stock to buy that even Warren Buffett likes
Trading at an 18% discount, this wide-moat stock is a rare find.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,969.20 | 82.60 | 0.93% |
| CAC 40 | 7,997.64 | 38.23 | -0.48% |
| DAX 40 | 25,357.00 | 42.21 | -0.17% |
| Dow JONES (US) | 51,349.92 | 131.59 | -0.26% |
| FTSE 100 | 10,655.23 | 18.52 | 0.17% |
| HKSE | 24,613.27 | 89.70 | 0.37% |
| NASDAQ | 26,797.54 | 22.84 | -0.09% |
| Nikkei 225 | 66,753.72 | 1,272.45 | 1.94% |
| NZX 50 Index | 13,834.39 | 150.76 | 1.10% |
| S&P 500 | 7,670.84 | 12.85 | -0.17% |
| S&P/ASX 200 | 8,789.30 | 80.00 | 0.92% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |